The Brisbane-based corporate team at McCullough Robertson is led by Reece Walker, a specialist in the life sciences, technology and telecoms sectors. The team also supports clients across the construction and engineering, transport and logistics, and resources and renewables industries, with a specific focus on assisting founders seeking capital raising advice at both the start-up and expansion capital phases. Ben Wood has particular expertise regarding financial services clients, while special counsel Naomi Omundson advises clients across Australia and the US with a notable emphasis on the life sciences sector.

Legal 500 Editorial commentary

Testimonials

Collated independently by Legal 500 research team.

  • ‘All dealings with McCullough Robertson equity capital markets practice have been commercially pragmatic, high quality and cost effective. The team generally communicates well and seeks practical solutions to challenges.'

  • ‘Reece Walker is a great leader and highly experienced lawyer with a common-sense and practical approach to issues. Highly responsive and thinks holistically.'

  • 'Ben Wood communicates and explains things well and is very competent. Very client focused and practical in the application of legal issues.'
  • 'Naomi Omundson is another outstanding member of the team with a practical approach, attention to detail, and excellent skills in communication and the application of the law.’

Key clients

  • LGI Limited
  • SOCO Corporation Limited
  • Imugene Limited
  • Prescient Therapeutics Limited
  • Chimeric Therapeutics Limited
  • Radiopharm Theranostics Limited
  • Implicit Bioscience Limited
  • Bell Potter Securities Limited and Canaccord Genuity (Australia) Limited
  • Diatreme Resources Limited
  • Group 6 Metals Limited
  • KGL Resources Limited
  • ECP Emerging Growth Limited

Work highlights

  • Advised LGI Limited in relation to its successful $25 million IPO, which resulted in a market cap of $130 million.
  • Assisted Imugene Limited in raising funds to provide an extended runway for Imugene’s deep pipeline of clinical programmes.
  • Assisted Prescient Therapeutics in raising funds to be used by PTX to progress its deep pipeline of innovative cancer therapies, namely the ongoing clinical development of its targeted therapies PTX-100 and PTX-200 and progressing its innovative cell therapies towards first-in-human clinical studies.

Practice head

The lawyer(s) leading their teams.

Reece Walker

Other key lawyers

Ben Wood, Aaron Dahl, Naomi Omundson